New York Chronicle

Delveinsight Business Research LLP

Some of the major pharma and biotech companies such as Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Geron Corporation, Karyopharm Therapeutics/Antengene Corporation, BerGenBio ASA, Bristol Myers Squibb, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac, Jasper Therapeutics, Vincerx Pharma and others are actively involved in developing therapies for Myelodysplastic Syndrome.

DelveInsight’s “Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myelodysplastic Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Myelodysplastic Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Myelodysplastic Syndrome: An Overview

Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. In MDS, also known as myelodysplasia, the bone marrow cells do not develop into mature blood cells; instead, these cells stay within the bone marrow in an immature state. There are many subtypes of MDS; some cases are mild, while others are more severe and carry a high risk of becoming acute myelogenous leukemia (AML).

MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include decreased red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable. Not all patients require treatment initially, as there is no survival benefit with the treatment of asymptomatic, low-risk patients.

There are many subtypes of MDS. The subtype is determined using the results of blood and bone marrow tests. MDS subtype is determined using either the World Health Organization (WHO) classification system or the French-American-British (FAB) classification system, but the WHO classification is more commonly used today.

Myelodysplastic Syndrome Market Key Facts

• In 2020, the incident population of MDS in the 7MM was 41,586.

• Epidemiology assessed for MDS showed that the US, in 2020, accounted for approximately 20,428 incident cases of MDS.

• In the US, based on the IPSS scoring, Low-risk MDS and High-risk MDS accounted for the highest and lowest cases, respectively, in 2020. On the other hand, based on the IPSS-R scoring, Low-risk MDS and Very high-risk MDS accounted for the highest and lowest cases, respectively, in 2020.

• Among the EU-5 countries in 2020, Germany had the highest incident population of MDS patients with 4,515 cases, followed by France (4,371) and the UK (3,302). In contrast, Spain had the lowest cases (2,010) in 2020.

• As per the estimates, Japan accounted for 3,909 incident MDS cases in 2020.

• Therapies like imetelstat, treosulfan, and SY-1425 + azacitidine, are expected to enter the market sooner than the other therapies, as their respective companies are planning to file for NDA soon.

Myelodysplastic Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Myelodysplastic Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Myelodysplastic Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Myelodysplastic Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Myelodysplastic Syndrome Epidemiology, Segmented as –

• Total Incident Population of Myelodysplastic Syndrome in the 7MM [2019–2032]

• Risk-specific Incident Population of Myelodysplastic Syndrome in the 7MM [2019–2032]

• Age-specific Incident Population of Myelodysplastic Syndrome in the 7MM [2019–2032]

• Subtype-specific Incident Population of Myelodysplastic Syndrome in the 7MM [2019–2032]

• Mutation-specific Incident Population of Myelodysplastic Syndrome in the 7MM [2019–2032]

Myelodysplastic Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Myelodysplastic Syndrome market or expected to be launched during the study period. The analysis covers the Myelodysplastic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myelodysplastic Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Myelodysplastic Syndrome Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

The Leading Players in the Myelodysplastic Syndrome Therapeutics Market Include:

• AbbVie

• Antengene Corporation

• Aprea Therapeutics

• Astex Pharmaceutical

• BerGenBio ASA

• Bristol Myers Squibb

• Bristol-Meyers Squibb

• Fibrogen

• Geron Corporation

• Gilead Sciences

• Jazz Pharmaceuticals

• Karyopharm Therapeutics

• Medac

• Novartis

• Pfizer

• Sanofi

• Syros pharmaceuticals

• Taiho Oncology

• Takeda

And Many Others

Myelodysplastic Syndrome Therapies Covered in the Report Include:

• Bemcentinib: BerGenBio ASA

• CPX-351: Jazz Pharmaceuticals

• Eltanexor (ATG 016; KPT-8602): Karyopharm Therapeutics/Antengene Corporation

• Enasidenib: Bristol Myers Squibb

• Eprenetapopt (APR-246): Aprea Therapeutics

• Fludarabine + Busulfan ± Clofarabine: Sanofi

• Glasdegib + Azacitidine: Pfizer

• Imetelstat: Geron Corporation

• Inqovi: Astex Pharmaceutical/Taiho Oncology

• Magrolimab ± Azacitidine: Gilead Sciences

• Pevonedistat ± Azacitidine: Takeda

• Reblozyl: Bristol-Meyers Squibb

• Roxadustat: Fibrogen

• Sabatolimab + Azacitidine: Novartis

• SY-1425 + Azacitidine: Syros pharmaceuticals

• Treosulfan ± fludarabine: Medac

• Venclexta (Venetoclax) + Azacitidine: AbbVie

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Myelodysplastic Syndrome Competitive Intelligence Analysis

4. Myelodysplastic Syndrome Market Overview at a Glance

5. Myelodysplastic Syndrome Disease Background and Overview

6. Myelodysplastic Syndrome Patient Journey

7. Myelodysplastic Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Myelodysplastic Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Myelodysplastic Syndrome Unmet Needs

10. Key Endpoints of Myelodysplastic Syndrome Treatment

11. Myelodysplastic Syndrome Marketed Products

12. Myelodysplastic Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Myelodysplastic Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Myelodysplastic Syndrome Market Outlook (In US, EU5, and Japan)

16. Myelodysplastic Syndrome Access and Reimbursement Overview

17. KOL Views on the Myelodysplastic Syndrome Market

18. Myelodysplastic Syndrome Market Drivers

19. Myelodysplastic Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/